Association between treatment (alirocumab (ALI) versus control) and achievement of (a) non-high-density lipoprotein cholesterol (non-HDL-C) goals or (b) both calculated low-density lipoprotein cholesterol (LDL-C) and non-HDL-C goals at Week 24 per baseline triglyceride (TG) quintiles.

Targets are non-HDL-C < 130 mg/dl in patients with moderate or high cardiovascular risk, and non-HDL-C < 100 mg/dl in patients with very-high cardiovascular risk. Log-scale for odds ratio. ALI 75/150 denotes that the dose could be increased from 75 to 150 mg at Week 12 depending on Week 8 LDL-C levels. CI: confidence interval; EZE: ezetimibe; PBO: placebo.